Abcam, ab232338, Anti-Junctional Adhesion Molecule 1/JAM-A antibody [EP1042Y] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal Junctional Adhesion Molecule 1/JAM-A antibody. Carrier free. Suitable for WB, IHC-P and reacts with Human samples. Cited in 2 publications.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EP1042Y,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:IHC-P, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab232338 is the carrier-free version of
ab52647
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Junctional Adhesion Molecule 1 also known as JAM-A or JAM-A protein is a member of the immunoglobulin superfamily. It has a mass of roughly 32 kDa. This molecule functions in tight junctions of epithelial and endothelial cells playing an important role in regulating paracellular permeability. JAM-A is expressed in tissues where tight junctions are present including the skin gastrointestinal tract and endothelia throughout the body.
Biological function summary
JAM-A functions as a cell adhesion molecule influencing processes like leukocyte transmigration and epithelial barrier formation. It does not act alone but rather forms complexes with other proteins at cell junctions. JAM-A interacts with other junctional proteins like occludin and claudins contributing to the structure and function of tight junctions.
Pathways
JAM-A participates in cellular processes involving inflammation and cell migration. It is an integral part of the signal transduction pathways that regulate leukocyte migration an important aspect of immune response. JAM-A is also associated with G-protein coupled receptors in these pathways highlighting its role in regulating intracellular signaling that affects cell adhesion and migration.
JAM-A has connections with cancer progression and cardiovascular diseases. Its overexpression has been linked to several cancers including breast cancer due to its role in enhancing cell migration and invasion. In cardiovascular diseases JAM-A interacts with platelet-endothelial cell adhesion molecule-1 (PECAM-1) influencing the inflammatory response within vascular tissues. Understanding these interactions can aid in developing therapeutic strategies targeting JAM-A in related diseases.